⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14030985 | 0.82 | CHRNB2 (0.40) | — | |
| SCHEMBL240843 | 0.82 | SMYD3 (0.39) | — | |
| SCHEMBL17959496 | 0.78 | — | — | |
| SCHEMBL30831319 | 0.78 | — | — | |
| SCHEMBL31226701 | 0.77 | KDR (0.35) | — | |
| SCHEMBL12844600 | 0.76 | — | — | |
| SCHEMBL10820280 | 0.76 | — | — | |
| SCHEMBL12498192 | 0.76 | — | — | |
| SCHEMBL1491435 | 0.76 | — | — | |
| SCHEMBL7675347 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12404248-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4201924-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240287004-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11945784-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-8143293-B2 | disease caused by c-Abl kinase, c-Kit kinase, oncogenic forms, aberrant fusion proteins and polymorphs; 1-(3-t-butylisoxazol-5-yl)-3-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)urea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2012019015-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
| CN-101801383-A | Kinase inhibitors for the treatment of myeloproliferative and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC | 2010-08-11 | — | — | CN | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-5086181-A | Promoter for animal feeds; animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | disclosed |
| US-4988694-A | Promoters for animal growth regulators for animal feeds | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| EP-0339345-A2 | 4-Bromo-6-chloro-5-amino-2-pyridyl-ethanol amines, process for their preparation and their use as performance stimulators | BAYER AG (DE) | 1989-11-02 | — | — | EP | disclosed |